As a preliminary assessment of the potential of RNAi against uPAR and cathepsin B as a therapeutic agent in growth inhibition, we assessed its in vitro apoptotic activity against U251 glioma and 5310 glioma xenograft cells. Here, CTSB is linked to central nervous system cancer.